+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
From
From
From
From
Hematopoietic Progenitor Kinase 1 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Hematopoietic Progenitor Kinase 1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Lung Adenocarcinoma Market Report and Forecast 2024-2032 - Product Thumbnail Image

Lung Adenocarcinoma Market Report and Forecast 2024-2032

  • Report
  • May 2024
  • 160 Pages
  • Global
From
Neuroendocrine Tumor Treatment Market in Canada - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in Canada

  • Report
  • February 2026
  • 150 Pages
  • Canada
From
Neuroendocrine Tumor Treatment Market in China - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in China

  • Report
  • February 2026
  • 150 Pages
  • China
From
Neuroendocrine Tumor Treatment Market in Germany - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in Germany

  • Report
  • February 2026
  • 150 Pages
  • Germany
From
Neuroendocrine Tumor Treatment Market in India - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in India

  • Report
  • February 2026
  • 150 Pages
  • India
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more